In this article, we will be taking a look at the 15 Innovative Healthcare Stocks to Buy According to Analysts.
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs. As concerns about value grow, investors are moving their funds from the crowded AI industry to sectors with more enticing risk-reward profiles. The healthcare industry is one significant sector that has profited immensely from this shift.
Since President Donald Trump’s deregulation initiatives have improved the climate for healthcare transactions, the industry has accelerated. Because of these factors, healthcare companies outperformed the MSCI World Index by 7.5% in the fourth quarter of 2025. Meanwhile, a new area of investment is developing at the intersection of AI and healthcare.
The need for AI-powered technologies that improve medical imaging, facilitate early disease identification, and speed up the development of new medications is growing. This trend was highlighted at the JPMorgan Healthcare Conference, when companies committed over $1 billion to AI computer capacity, knowledge, and infrastructure.
The healthcare industry has strong long-term fundamentals, including expected annualized profits growth of 11.5%, which is higher than most equity sectors, despite short-term volatility. Investment is also anticipated to be encouraged by lower interest rates and better financing circumstances, especially for businesses with obvious commercialization routes.
Medicare Advantage reimbursement is still unclear, though. In January, Mizuho strategist Jared Holz noted that a Trump administration proposal calling for only a 0.09% payment increase shocked investors and pressured major insurers. Ahead of the April decision, Holz stressed that the proposal is not final and may be improved. He thinks concerns about a structural downturn are exaggerated, seeing the current state of affairs as a brief lull rather than the conclusion of the sector’s long-term development narrative, even though earnings growth may be reduced for the next year or two.
Our Methodology
For our methodology, we began by filtering innovative healthcare stocks with a market capitalization above $2 billion and a positive analyst upside of at least 20% as of February 9. From this list, we selected the top 15 companies and ranked them in ascending order based on their price target upside.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Here is our list of the 15 innovative healthcare stocks to buy according to analysts.
15. Prestige Consumer Healthcare Inc. (NYSE:PBH)
Price Target Upside: 22.36%
Prestige Consumer Healthcare Inc. (NYSE:PBH) stands fifteenth on our list of best healthcare stocks.
TheFly reported on February 6 that Canaccord reduced its price target on PBH to $86 from $88 and maintained a Buy rating on the shares. The change came after the company reported fiscal third-quarter sales of $283.4 million, a 2.4% year-over-year decline. This amount was roughly in line with company projections and came in just over the $282.0 million that the Street had anticipated. According to management, the Clear Eyes brand’s supply issues were the main cause of the sales drop.
Moreover, on February 5, Prestige Consumer Healthcare Inc. (NYSE:PBH) reported third-quarter net income, which totaled $46.7 million, while adjusted net income reached $54.9 million. Diluted EPS of $0.97, while adjusted diluted EPS came in at $1.14, compared with $1.22 in the same quarter last year. The company also finalized the acquisition of Pillar5 Pharma and repurchased about 0.8 million shares during the quarter. While maintaining projections for free cash flow of at least $245 million, the corporation also reduced its fiscal 2026 sales outlook to about $1.1 billion.
Prestige Consumer Healthcare Inc. (NYSE:PBH) is a U.S. over-the-counter healthcare company that markets and innovates trusted wellness brands and continuously improves products to meet evolving consumer needs while expanding its portfolio and global reach in OTC care.
14. Alignment Healthcare, Inc. (NASDAQ:ALHC)
Price Target Upside: 22.89%
The next stock on our list is Alignment Healthcare, Inc. (NASDAQ:ALHC).
TheFly reported on January 30 that Baird increased its price target on ALHC to $28 from $22 while maintaining an Outperform rating. After updating its financial model, the firm now believes there is significant upside potential and that the shares might rise to $59, or around 163% over their present price.
Separately, John E. Kao, the CEO of Alignment Healthcare, Inc. (NASDAQ:ALHC), recently sold 180,000 shares on February 10 for a total of about $3.68 million at a weighted-average price of $20.4853. The individual deals ranged from $20.23 to $20.66. A pre-established Rule 10b5-1 trading plan that was adopted on March 12, 2025, was used to perform the trade.
After the sale, Kao still owns more than 2.6 million shares indirectly through a trust in which he acts as trustee and more than 1.5 million shares personally. The stock has risen 21.7% over the last six months. Despite the company’s lack of profitability over the last 12 months, analysts predict profitability this year, with an expected FY2025 EPS of $0.23. ALHC is also anticipated to report its earnings on February 26, 2026.
Alignment Healthcare, Inc. (NASDAQ:ALHC) is a U.S. tech-enabled Medicare Advantage company innovating senior care with AI-driven data analytics through its proprietary AVA platform to proactively predict and personalize care, which is supported by a 24/7 concierge model that improves outcomes, access, and member experience.
13. Concentra Group Holdings Parent, Inc. (NYSE:CON)
Price Target Upside: 23.98%
The thirteenth stock on our list of best healthcare stocks is Concentra Group Holdings Parent, Inc. (NYSE:CON).
TheFly reported on February 2 that RBC Capital raised its price target on CON to $31 from $30 and maintained an Outperform rating. The hike comes after the company’s Q4 pre-announcement, which was above the consensus, and its early projection for FY2026. RBC stated that despite continuous macroeconomic instability, CON’s business model is inherently stable, as seen by its solid Q4 performance.
Concentra Group Holdings Parent, Inc. (NYSE:CON) stated on January 28 that it anticipates FY2026 revenue to be between $2.25 billion and $2.35 billion, which is just below the $2.32 billion consensus forecast. The company also continues to expand, announcing on January 26 the opening of a new medical center in Georgia. This move supports CON’s long-term revenue growth and market position while demonstrating the company’s continued commitment to expanding access to its occupational health and wellness services.
Concentra Group Holdings Parent, Inc. (NYSE:CON) is the largest U.S. occupational health services provider, innovating workforce healthcare with tech‑enabled care, telemedicine, and an expanding network of onsite clinics that improve employee health access, efficiency, and outcomes while driving growth through strategic acquisitions and integrated service solutions.
